YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration

References

• Tang Q, Xie M, Yu S, Zhou X, Xie Y, Chen G, Guo F, Chen L. Periodic oxaliplatin administration in synergy with PER2-Mediated PCNA transcription repression promotes chronochemotherapeutic efficacy of OSCC. Adv Sci (Weinh). 2019;6(21):1900667. doi:10.1002/advs.201900667.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–18. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang X, Fu Y, Liu Y, Zheng L, Liu F, Li T, Yin X, Qiao X, Xu X. Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma. EBioMedicine. 2019;47:44–57. doi:10.1016/j.ebiom.2019.08.013.
   PubMed Web of Science ®Google Scholar
• Colli ML, Hill JLE, Marroqui L, Chaffey J, Dos Santos RS, Leete P, Coomans De Brachene A, Paula FMM, Op De Beeck A, Castela A, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018;36:367–375. doi:10.1016/j.ebiom.2018.09.040.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–965. doi:10.1016/S1470-2045(16)30066-3.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li ZY, Zhou GQ, Sun Y. An immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2020. doi:10.1158/1078-0432.CCR-20-2166.
   Google Scholar
• Chai AWY, Lim KP, Cheong SC. Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2020;61:71–83. doi:10.1016/j.semcancer.2019.09.011.
   PubMed Web of Science ®Google Scholar
• Menares E, Galvez-Cancino F, Caceres-Morgado P, Ghorani E, Lopez E, Diaz X, Saavedra-Almarza J, Figueroa DA, Roa E, Quezada SA, et al. Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells. Nat Commun. 2019;10(1):4401. doi:10.1038/s41467-019-12319-x.
   PubMed Web of Science ®Google Scholar
• Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res. 2016;22(9):2261–2270. doi:10.1158/1078-0432.CCR-15-2834.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, Miyakawa A, Kobayashi J, Kaneko T, Igarashi T, et al. Tumor-infiltrating CD8(+) T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8(1):80–93. doi:10.1002/cam4.1889.
   PubMed Web of Science ®Google Scholar
• Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery JP, Chouaib S. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11(7):824–846. doi:10.1002/1878-0261.12093.
   PubMed Web of Science ®Google Scholar
• Li B, Cui Y, Nambiar DK, Sunwoo JB, Li R. The immune subtypes and landscape of squamous cell carcinoma. Clin Cancer Res. 2019;25(12):3528–3537. doi:10.1158/1078-0432.CCR-18-4085.
   PubMed Web of Science ®Google Scholar
• Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol. 2019;30(1):68–75. doi:10.1093/annonc/mdy470.
   PubMed Web of Science ®Google Scholar
• Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao L, Zhang WF, Liu B, Sun ZJ. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother. 2017;66(5):627–636. doi:10.1007/s00262-017-1968-0.
   PubMed Web of Science ®Google Scholar
• Wu L, Deng WW, Yu GT, Mao L, Bu LL, Ma SR, Liu B, Zhang WF, Sun ZJ. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma. Cancer Immunol Immunother. 2016;65(9):1035–1045. doi:10.1007/s00262-016-1867-9.
   PubMed Web of Science ®Google Scholar
• Das D, Ghosh S, Maitra A, Biswas NK, Panda CK, Roy B, Sarin R, Majumder PP. Epigenomic dysregulation-mediated alterations of key biological pathways and tumor immune evasion are hallmarks of gingivo-buccal oral cancer. Clin Epigenetics. 2019;11(1):178. doi:10.1186/s13148-019-0782-2.
   PubMed Web of Science ®Google Scholar
• Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47(12):1148–1153. doi:10.1016/j.oraloncology.2011.08.007.
   PubMed Web of Science ®Google Scholar
• Fukasawa M, Varlamov O, Eng WS, Sollner TH, Rothman JE. Localization and activity of the SNARE Ykt6 determined by its regulatory domain and palmitoylation. Proc Natl Acad Sci U S A. 2004;101(14):4815–4820. doi:10.1073/pnas.0401183101.
   PubMed Web of Science ®Google Scholar
• Ruiz-Martinez M, Navarro A, Marrades RM, Vinolas N, Santasusagna S, Munoz C, Ramirez J, Molins L, Monzo M. YKT6 expression, exosome release, and survival in non-small cell lung cancer. Oncotarget. 2016;7(32):51515–51524. doi:10.18632/oncotarget.9862.
   PubMedGoogle Scholar
• Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt proteins are secreted on exosomes. Nat Cell Biol. 2012;14(10):1036–1045. doi:10.1038/ncb2574.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Matsui T, Yamamoto H. YKT6 as a second SNARE protein of mammalian autophagosomes. Autophagy. 2019;15(1):176–177. doi:10.1080/15548627.2018.1532262.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Kluger Y, Gilmore-Hebert M, DiVito K, Chang JT, Rodov S, Mironenko O, Kacinski BM, Perkins AS, Sapi E. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest. 2004;84(3):320–331. doi:10.1038/labinvest.3700044.
   PubMed Web of Science ®Google Scholar
• Ooe A, Kato K, Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat. 2007;101(3):305–315. doi:10.1007/s10549-006-9293-x.
   PubMed Web of Science ®Google Scholar
• Saito Y, Li L, Coyaud E, Luna A, Sander C, Raught B, Asara JM, Brown M, Muthuswamy SK. LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer. Nature. 2019;569(7755):275–279. doi:10.1038/s41586-019-1126-2.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB, Abu-Akeel M, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843–52 e4. doi:10.1016/j.ccell.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, et al. EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. Epigenetics. 2019;14(2):118–129. doi:10.1080/15592294.2019.1573066.
   PubMed Web of Science ®Google Scholar
• Zhao W, Cui Y, Liu L, Qi X, Liu J, Ma S, Hu X, Zhang Z, Wang Y, Li H, et al. Correction to: splicing factor derived circular RNA circUHRF1 accelerates oral squamous cell carcinoma tumorigenesis via feedback loop. Cell Death Differ. 2020;27(6):2033–2034. doi:10.1038/s41418-019-0477-4.
   PubMed Web of Science ®Google Scholar
• Lu X, Jiang L, Zhang L, Zhu Y, Hu W, Wang J, Ruan X, Xu Z, Meng X, Gao J, et al. Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression, molecular features, and clinical outcome. Neoplasia. 2019;21(6):591–601. doi:10.1016/j.neo.2019.04.003.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Lin K, Song LJ, Ma J, Zhang TS, You DY, He YW. Identification of cancer hallmark-associated gene and lncRNA cooperative regulation pairs and dictate lncRNA roles in oral squamous cell carcinoma. J Cell Mol Med. 2020;24(9):5213–5223. doi:10.1111/jcmm.15174.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582. doi:10.1038/nature14129.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, et al. The Immune Landscape of Cancer. Immunity. 2019;51(2):411–412. doi:10.1016/j.immuni.2019.08.004.
   PubMed Web of Science ®Google Scholar
• Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Shi X, Wang B, Li Z, Ren P, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420–D30. doi:10.1093/nar/gkaa1020.
   PubMed Web of Science ®Google Scholar
• Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 2011;9(2):161–172. doi:10.1158/1541-7786.MCR-10-0386.
   PubMed Web of Science ®Google Scholar
• Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and −9 expressions. Int J Oncol. 2010;37(3):663–668. doi:10.3892/ijo_00000715.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW Jr., Chatterjee SK. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells. J Cell Biochem. 2006;97(5):1036–1051. doi:10.1002/jcb.20647.
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900 e10. doi:10.1016/j.ccell.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shi M, Chen T, Zhang B. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy. Mol Ther Nucleic Acids. 2020;22:298–309. doi:10.1016/j.omtn.2020.08.030.
   PubMedGoogle Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. 2019:8. doi:10.7554/eLife.49020.
   Web of Science ®Google Scholar
• Carlisle JW, Steuer CE, Owonikoko TK, Saba NF. An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. 2020;70(6):505–517. doi:10.3322/caac.21630.
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu YX. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 Blockade. Cancer Cell. 2016;30(3):500. doi:10.1016/j.ccell.2016.08.011.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, De Castro G Jr., Psyrri A, Baste N, Neupane P, Bratland A, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar
• Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, et al. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020;12(1):83. doi:10.1186/s13073-020-00780-z.
   PubMed Web of Science ®Google Scholar
• Gu J, Zhang J, Huang W, Tao T, Huang Y, Yang L, Yang J, Fan Y, Wang H. Activating miRNA-mRNA network in gemcitabine-resistant pancreatic cancer cell associates with alteration of memory CD4+ T cells. Ann Transl Med. 2020;8(6):279. doi:10.21037/atm.2020.03.53.
   PubMed Web of Science ®Google Scholar
• McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2021;39(1):30–37. doi:10.1200/JCO.20.00290.
   PubMed Web of Science ®Google Scholar
• Xiao C, Song F, Zheng YL, Lv J, Wang QF, Xu N. Exosomes in head and neck squamous cell carcinoma. Front Oncol. 2019;9:894. doi:10.3389/fonc.2019.00894.
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, et al. Suppression of Exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414–27 e13. doi:10.1016/j.cell.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Parpal S, Van Moer K, Xiao M, Yu Y, Viklund J, De Milito A, Andersson M, Andersson M, Amaravadi RK, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy. Sci Adv. 2020;6(18):eaax7881. doi:10.1126/sciadv.aax7881.
   PubMed Web of Science ®Google Scholar
• Lawson KA, Sousa CM, Zhang X, Kim E, Akthar R, Caumanns JJ, Yao Y, Mikolajewicz N, Ross C, Brown KR, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586(7827):120–126. doi:10.1038/s41586-020-2746-2.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100–105. doi:10.1038/s41586-020-2229-5.
   PubMed Web of Science ®Google Scholar
• Han C, Chen T, Yang M, Li N, Liu H, Cao X. Human SCAMP5, a novel secretory carrier membrane protein, facilitates calcium-triggered cytokine secretion by interaction with SNARE machinery. J Immunol. 2009;182(5):2986–2996. doi:10.4049/jimmunol.0802002.
   PubMed Web of Science ®Google Scholar
• Kweon Y, Rothe A, Conibear E, Stevens TH. Ykt6p is a multifunctional yeast R-SNARE that is required for multiple membrane transport pathways to the vacuole. Mol Biol Cell. 2003;14(5):1868–1881. doi:10.1091/mbc.e02-10-0687.
   PubMed Web of Science ®Google Scholar
• Naydenov NG, Joshi S, Feygin A, Saini S, Litovchick L, Ivanov AI. A membrane fusion protein, Ykt6, regulates epithelial cell migration via microRNA-mediated suppression of junctional adhesion molecule A. Cell Cycle. 2018;17(14):1812–1831. doi:10.1080/15384101.2018.1496755.
   PubMed Web of Science ®Google Scholar
• Fletcher SJ, Rappoport JZ. The role of vesicle trafficking in epithelial cell motility. Biochem Soc Trans. 2009;37(5):1072–1076. doi:10.1042/BST0371072.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. doi:10.1016/j.cell.2010.03.015.
   PubMed Web of Science ®Google Scholar
• Lee SB, Park YS, Sung JS, Lee JW, Kim B, Kim YH. Tumor suppressor miR-584-5p inhibits migration and invasion in smoking related non-small cell lung cancer cells by targeting YKT6. Cancers (Basel). 2021;13(5). doi:10.3390/cancers13051159.
   Web of Science ®Google Scholar
• Derynck R, Turley SJ, Akhurst RJ. TGFbeta biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi:10.1038/s41571-020-0403-1.
   PubMed Web of Science ®Google Scholar
• Cillo AR, Kurten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183–99 e9. doi:10.1016/j.immuni.2019.11.014.
   PubMed Web of Science ®Google Scholar